MetaCap

Protara Therapeutics Inc. (TARA)

NASDAQ: TARAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

2.28-0.12 (-5.00%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

TARA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$140.38M
EPS (TTM)
-$1.39
52-week range
2.09 – 7.82
Day range
2.25 – 2.42
Volume / Avg
1.07M / 1.07M
Beta
—

52-week range

$2.09$7.82

TARA stock today

Shares of Protara Therapeutics (TARA) finished lower on Nov 20 at $2.28, a drop of 5.00% or $0.12 per share, versus the S&P 500's 3.70% decline. At this level, TARA sits near the bottom of its 52-week range of $2.09 to $7.82: 70.8% below the high, set on Nov 24, 2025 and 9.1% above the low. TARA is down 57.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 68.6%.

Protara Therapeutics has posted a net loss over the last twelve months (EPS of -$1.39), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Protara Therapeutics

Company profile

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Jesse Shefferman
Headquarters
New York, NY
Employees
46
IPO year
2014

Financial highlights

Full financials

Protara Therapeutics reported a net loss of $57.4 million, compared with a loss of $44.6 million a year earlier. Diluted earnings per share came in at -$1.34.

Protara Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-57.44M$-44.60M$-40.42M$-65.95M$-47.25M
EPS (diluted)$-1.34$-2.17$-3.57$-5.86$-4.21

Analyst forecast

Forecast

Consensus (8 analysts)

strong_buy

Avg. price target

$25.33+1010.96%

  • Strong buy 2
  • Buy 6
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $18.00High $30.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.35 vs $-0.37
Surprise
+5.41%

TARA news

All TARA news

Protara Therapeutics peers

Health Care sector
TARA peer companies
CompanyPrice% ChgMarket capCompare
STROSutro Biopharma Inc.8.60-1.38%$142.77Mvs TARA
PALIPalisade Bio Inc.0.8399-9.24%$150.74Mvs TARA
CMPXCompass Therapeutics Inc.0.6882+1.43%$123.94Mvs TARA
HUMAHumacyte Inc.0.4454-17.90%$123.73Mvs TARA
IVVDInvivyd Inc.0.4127-7.45%$122.01Mvs TARA
ENGNenGene Therapeutics Inc.1.74-1.14%$116.61Mvs TARA
ARMPArmata Pharmaceuticals Inc.3.03+1.68%$112.69Mvs TARA
FATEFate Therapeutics Inc.0.919-9.01%$111.82Mvs TARA

Indexes, lists and sector

Protara Therapeutics stock FAQ

What is Protara Therapeutics's stock price today?

TARA last traded at $2.28 as of Nov 20, 4:00 PM EST, down 5.00% on the day. Prices are delayed at least 15 minutes.

Does Protara Therapeutics pay a dividend?

No. Protara Therapeutics does not currently pay a regular cash dividend.

Who is Protara Therapeutics's CEO?

Mr. Jesse Shefferman is the chief executive officer of Protara Therapeutics Inc., which has about 46 employees.

Has TARA ever split its stock?

Yes. The most recent TARA stock split was a 1-for-40 split on Jan 10, 2020.

What is the TARA 52-week high?

The 52-week high for TARA is $7.82 and the 52-week low is $2.09. The stock is currently 70.8% below its high.

Compare TARA